Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H7BrN4O2.C4H11NO |
Molecular Weight | 348.196 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(N)CO.CN1C2=C(N=C(Br)N2)C(=O)N(C)C1=O
InChI
InChIKey=ATOTUUBRFJHZQG-UHFFFAOYSA-N
InChI=1S/C7H7BrN4O2.C4H11NO/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14;1-4(2,5)3-6/h1-2H3,(H,9,10);6H,3,5H2,1-2H3
Molecular Formula | C4H11NO |
Molecular Weight | 89.1362 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C7H7BrN4O2 |
Molecular Weight | 259.06 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL318 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8410976 |
10.2 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | DIUREX Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3685.6 ng/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
BROMOTHEOPHYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
46210.49 ng × h/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
BROMOTHEOPHYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.35 h |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
BROMOTHEOPHYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
25 mg 1 times / day multiple, oral Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Co-administed with:: 2-amino-2-methyl-1-propanol Sources: |
unhealthy, 26 years n = 1 Health Status: unhealthy Age Group: 26 years Sex: F Population Size: 1 Sources: |
Disc. AE: Fixed drug eruption... AEs leading to discontinuation/dose reduction: Fixed drug eruption Sources: |
900 mg 1 times / day multiple, oral Highest studied dose Dose: 900 mg, 1 times / day Route: oral Route: multiple Dose: 900 mg, 1 times / day Co-administed with:: 2-amino-2-methyl-1-propanol Sources: |
unhealthy, 44-78 years n = 1 Health Status: unhealthy Condition: cardiac failure Age Group: 44-78 years Sex: M+F Population Size: 1 Sources: |
Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (mild, 1 patient) Sources: |
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Co-administed with:: 2-amino-2-methyl-1-propanol Sources: |
unhealthy, 44-78 years n = 18 Health Status: unhealthy Condition: cardiac failure Age Group: 44-78 years Sex: M+F Population Size: 18 Sources: |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (severe, 4 patients) Sources: Vomiting (severe, 4 patients) Skin rash (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Fixed drug eruption | Disc. AE | 25 mg 1 times / day multiple, oral Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Co-administed with:: 2-amino-2-methyl-1-propanol Sources: |
unhealthy, 26 years n = 1 Health Status: unhealthy Age Group: 26 years Sex: F Population Size: 1 Sources: |
Diarrhea | mild, 1 patient Disc. AE |
900 mg 1 times / day multiple, oral Highest studied dose Dose: 900 mg, 1 times / day Route: oral Route: multiple Dose: 900 mg, 1 times / day Co-administed with:: 2-amino-2-methyl-1-propanol Sources: |
unhealthy, 44-78 years n = 1 Health Status: unhealthy Condition: cardiac failure Age Group: 44-78 years Sex: M+F Population Size: 1 Sources: |
Skin rash | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Co-administed with:: 2-amino-2-methyl-1-propanol Sources: |
unhealthy, 44-78 years n = 18 Health Status: unhealthy Condition: cardiac failure Age Group: 44-78 years Sex: M+F Population Size: 18 Sources: |
Nausea | severe, 4 patients Disc. AE |
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Co-administed with:: 2-amino-2-methyl-1-propanol Sources: |
unhealthy, 44-78 years n = 18 Health Status: unhealthy Condition: cardiac failure Age Group: 44-78 years Sex: M+F Population Size: 18 Sources: |
Vomiting | severe, 4 patients Disc. AE |
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Co-administed with:: 2-amino-2-methyl-1-propanol Sources: |
unhealthy, 44-78 years n = 18 Health Status: unhealthy Condition: cardiac failure Age Group: 44-78 years Sex: M+F Population Size: 18 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
A study of diuretic action of pamabrom (2-amino-2-methyl-propanol-1-8-bromotheophylline) in cardiac failure. | 1953 Aug |
|
Fixed drug eruption caused by pamabrom. | 2009 Oct |
|
Erythema multiforme secondary to dimenhydrinate in a patient with previous similar reactions to pamabrom. | 2014 Mar |
Patents
Sample Use Guides
Adults: Take one (1) capsule after breakfast with a full glass of water. Dose may be repeated after six (6) hours, not to exceed four (4) capsules per day. Start taking 5 or 6 days before onset of period and continue until desired relief is obtained or end of period. Drink 6 to 8 glasses of water daily.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:08:30 GMT 2023
by
admin
on
Fri Dec 15 15:08:30 GMT 2023
|
Record UNII |
UA8U0KJM72
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
734
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
||
|
NCI_THESAURUS |
C448
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
||
|
CFR |
21 CFR 310.201
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID80209397
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
C81076
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
C069987
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
54365
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT002688
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
UA8U0KJM72
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
606-04-2
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
100000079715
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
Pamabrom
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
SUB14745MIG
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
UA8U0KJM72
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
210-103-4
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
2047
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL316160
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | |||
|
m8371
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
11806
Created by
admin on Fri Dec 15 15:08:30 GMT 2023 , Edited by admin on Fri Dec 15 15:08:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |